Phaseline

Companies › Epsilogen

Epsilogen: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MOv18 IgE
Anti-folate receptor alpha (FRα) monoclonal antibody of the IgE class
FOLR1Phase 1Advanced Ovarian CancerMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06547840MOv18 IgEPhase 1Advanced Ovarian CancerOncologyMar 2027

Targets

FOLR1 (1)

Companies with the same targets

AbbVie Phrontline Biopharma Beijing Biotech Eisai Changchun GeneScience Pharmaceutical Takeda CSPC Megalith Biopharmaceutical AstraZeneca

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.